Clinical trials: Metastasis to Liver
Colorectal Cancer, Liver Metastases
French Assessment of MRD by Liquid Biopsies in Colorectal With Liver Metastasis Patients (FRENCH.MRD.CRLM)
Improving personalized cancer treatments and finding the best strategies to treat each patient relies on using new diagnostic technologies.
- Conditions
- Colorectal Cancer, Liver Metastases, Stage IV Colorectal Cancer, Minimal Residual Disease
- Trial name
- NCT06287723
- Testing
- Blood sample/Liquid biopsy
- Where
- 2 sites in France
- Volunteers
- 30 people
- Sponsor
- University Hospital, Montpellier
Colorectal Cancer, Liver Metastasis Colon Cancer
Fluorescence-guided Resection Of Colorectal Liver Metastases Using SGM-101 and Indocyanine GREEN
This will be the first trial testing the feasibility of working simultaneously with the two fluorescent dyes ICG and SGM-101 in 10 patients with colorectal metastases.
- Conditions
- Colorectal Cancer, Liver Metastasis Colon Cancer, Image
- Trial name
- FOCUS GREEN (NCT05965817)
- Testing
- SGM-101 op top of ICG
- Where
- Netherlands
- Volunteers
- 10 people
- Sponsor
- Leiden University Medical Center
Non-alcoholic Fatty Liver Disease, Nonalcoholic Steatohepatitis
A Clinical Study of Efinopegdutide in People With Compensated Cirrhosis Due to Steatohepatitis (MK-6024-017)
Researchers are looking for ways to treat a type of liver disease caused by elevated liver fat, called metabolic dysfunction-associated steatohepatitis (MASH). MASH was formerly called non-alcoholic steatohepatitis (NASH).
- Conditions
- Non-alcoholic Fatty Liver Disease, Nonalcoholic Steatohepatitis, NAFLD, Metabolic Dysfunction-associated Steatotic Liver Disease
- Trial name
- NCT06465186
- Testing
- Efinopegdutide
- Where
- 68 sites in United States, Australia and 9 more
- Volunteers
- 85 people
- Sponsor
- Merck Sharp & Dohme LLC
Colorectal Cancer Metastatic
Neoadjuvant Safety of Sintilimab + XELOX + Bevacizumab in PMMR/MSS CRLM Patients
This prospective, single arm study aims to evaluate the preoperative neoadjuvant safety of Sintilimab combined with XELOX plus bevacizumab in colorectal patients with liver metastasis and pMMR/MSS status.
- Trial name
- NCT04940546
- Testing
- Sintilimab, Oxaliplatin, Capecitabine
- Where
- China
- Volunteers
- 36 people
- Sponsor
- Sun Yat-sen University
Colorectal Cancer, Liver Metastasis
Surgical Recovery After Left Lateral Hepatic Sectionectomy: Laparoscopic Versus Open Surgery.
The ORANGE II trial is a double blinded randomised controlled trial that will provide evidence on the merits of laparoscopic surgery in patients undergoing a left lateral hepatic sectionectomy in terms of time to functional…
- Conditions
- Colorectal Cancer, Liver Metastasis, Liver Disease
- Trial name
- ORANGE II (NCT00874224)
- Testing
- laparoscopic left lateral hepatic sectionectomy, open left lateral hepatic sectionectomy
- Where
- Netherlands
- Volunteers
- 110 people, healthy volunteers welcome
- Sponsor
- Maastricht University Medical Center
Carcinoma, Hepatocellular
A Dose-Finding and Exploratory Study of RO5323441 in Combination With Sorafenib in Patients With Hepatocellular Carcinoma
This open-label study will assess the safety, efficacy and pharmacokinetics of RO5323441 in combination with sorafenib in patients with advanced or metastatic hepatocellular carcinoma previously untreated with systemic therapy.
- Trial name
- NCT01308723
- Testing
- RO5323441, sorafenib
- Where
- 2 sites in Singapore
- Volunteers
- 6 people
- Sponsor
- Hoffmann-La Roche
Colorectal Carcinoma, Chemotherapy
Microwave Ablation Combined With Chemotherapy for Colorectal Liver Metastases： a Multicenter Cohort Study
Colorectal cancer is the second deadliest malignant tumor worldwide, and liver is the most common site of hematogenic metastasis of Colorectal cancer.
- Conditions
- Colorectal Carcinoma, Chemotherapy, Liver Metastases
- Trial name
- NCT04562727
- Testing
- Chemotherapy
- Volunteers
- 668 people
- Sponsor
- Ping Liang
Colorectal Cancer, Liver Metastases
The Prediction Model of Avastin Plus Chemotherapy in Unresectable Ras Mutant CRLM Patients
establishment and validation of the prediction model of avastin plus chemotherapy as first line treatment in simultaneous ras mutant unresectable CRLM patients
- Trial name
- NCT04525313
- Volunteers
- 116 people
- Sponsor
- Fudan University
Liver Metastases
Hepatoprotective Effect of Remote vs Local Preconditioning of Liver
The aim of this study is to evaluate hepatoprotective effect from ischemia-reperfusion injury of remote ischemic preconditioning of the liver against local ischemic preconditioning of the liver during human liver resections.
- Trial name
- NCT03130920
- Testing
- Preconditioning
- Where
- Croatia
- Volunteers
- 60 people
- Sponsor
- University Hospital Dubrava
Colorectal Liver Metastasis
Minimally Invasive Versus Open Liver Resection for Patients With Colorectal Cancer Liver Metastases
To examine survival of patients who underwent minimally invasive versus open liver resection for colorectal cancer with liver metastases.
- Trial name
- NCT03895723
- Testing
- laparoscopic and robotic liver resection, open surgery
- Where
- China
- Volunteers
- 220 people
- Sponsor
- Xu jianmin
Colorectal Cancer, Liver Metastases
Impact of Positron Emission Tomography Imaging Prior to Liver Resection for Colorectal Adenocarcinoma Metastases
The purpose of this trial is to improve the management of patients with potentially surgically curable colorectal cancer liver metastases.
- Trial name
- PETCAM (NCT00265356)
- Testing
- PET diagnostic imaging
- Where
- 9 sites in Canada
- Volunteers
- 404 people
- Sponsor
- Ontario Clinical Oncology Group (OCOG)
Colorectal Cancer, Liver Metastases
COLDFIRE-III Trial: Efficacy of Irreversible Electroporation and Stereotactic Body Radiotherapy for Perivascular and Peribiliary Colorectal Liver Metastases
The primary objective of this phase IIb/III, prospective, randomized clinical trial is to compare the efficacy of irreversible electroporation (IRE) with stereotactic body radiotherapy (SBRT) in patients with perivascular or…
- Conditions
- Colorectal Cancer, Liver Metastases, Liver Metastasis Colon Cancer, Unresectable Solid Tumor
- Trial name
- COLDFIRE-III (NCT06185556)
- Testing
- Irreversible electroporation, Stereotactic body radiotherapy
- Where
- Netherlands
- Volunteers
- 78 people
- Sponsor
- Amsterdam UMC, location VUmc
Colorectal Cancer, Metastatic Cancer
Combination Chemotherapy With or Without Cetuximab Before and After Surgery in Treating Patients With Resectable Liver Metastases Caused By Colorectal Cancer
RATIONALE: Drugs used in chemotherapy, such as oxaliplatin, fluorouracil, leucovorin, and capecitabine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00482222
- Testing
- cetuximab, capecitabine, fluorouracil
- Where
- 22 sites in United Kingdom
- Volunteers
- 340 people
- Sponsor
- University of Southampton
Melanoma Stage IV
Study of Oncolytic Virus in Combination With HX-008 and Radiotherapy in Melanoma Patients With Liver Metastasis
Malignant melanoma, is a kind of malignant tumor derived from melanocytes. It is common in skin, mucous membrane, eye choroid and other parts.
- Trial name
- NCT05068453
- Testing
- Recombinant Oncolytic HSV-2 Therapeutic Injecta (Vero Cell) for Human Use (rHSV2hGM-CSF), Recombinant humanized anti-PD-1 monoclonal antibody for injection, RT
- Volunteers
- 15 people
- Sponsor
- Peking University Cancer Hospital & Institute
Colorectal Cancer
Cetuximab/FOLFIRI With or Without Oxaliplatin and FOLFOXIRI With or Without Bevacizumab in Neoadjuvant Treatment of Non-resectable Colorectal Liver Metastases
The aim of this study is to investigate the following schedules for efficacy with regard to response rate in neoadjuvant treatment of patients with non-resectable liver metastases: Cetuximab/FOLFOXIRI and cetuximab/FOLFIRI in…
- Trial name
- CELIM2 (NCT01802645)
- Testing
- Cetuximab, Bevacizumab, Irinotecan
- Where
- 15 sites in Germany
- Volunteers
- 91 people
- Sponsor
- Technische Universität Dresden
Pancreatic Neoplasms, Neoplasm Metastasis
Oxaliplatin Combined With Irinotecan Liposome Injection II Through Hepatic Artery Infusion (HAIC) Followed by 5-FU/LV (HAIC) or Tegorgor Oral Combination Therapy for Hepatic Metastasis of Pancreatic Cancer
The study explores the efficacy and safety of oxaliplatin combined with irinotecan liposome injection II via hepatic arterial infusion (HAIC) followed by sequential treatment with 5-FU/LV (HAIC) or oral administration of S-1 in…
- Conditions
- Pancreatic Neoplasms, Neoplasm Metastasis, Hepatic Metastasis of Pancreatic Cancer
- Trial name
- NCT06538623
- Testing
- Liposome Irinotecan Injection II combined with Oxaliplatin, Fluorouracil, Leucovorin, Tegodor
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Ruijin Hospital
Esophageal and Gastric Varices
Carvedilol as an Adjunct to Endoscopic Cyanoacrylate Injection for Secondary Prophylaxis of Gastric Variceal Bleeding
Gastric variceal obturation is the current endoscopic therapy of choice for gastric variceal bleeding but is associated with a high rebleeding rate. Carvedilol is a potent non-selective β-blocker.
- Trial name
- NCT02504723
- Testing
- carvedilol, cyanoacrylate
- Where
- Taiwan
- Volunteers
- 121 people
- Sponsor
- Kaohsiung Veterans General Hospital.
Colorectal Cancer Stage III, Liver Metastasis Colon Cancer
GUIDE.MRD-01-CRC: Clinical Validation and Benchmarking of Top Performing ctDNA Diagnostics - Colorectal Cancer
Improving personalized cancer treatments and finding the best strategies to treat each patient relies on using new diagnostic technologies.
- Trial name
- NCT06111105
- Where
- 15 sites in Austria, Denmark and 3 more
- Volunteers
- 590 people
- Sponsor
- Claus Lindbjerg Andersen
Metastatic Colorectal Cancer
Phase II Study Comparing Conversion Rate to Surgery With Hepatic Arterial Infusion Chemotherapy to Systemic Chemotherapy in Patients With Non Resectable Liver-only Colorectal Metastases
Approximately 40% of colorectal cancer patients will develop colorectal liver metastases (CRLM). The most effective approach to increase long-term survival is CRLM complete resection.
- Trial name
- NCT05103020
- Testing
- intra-arterial oxaliplatin + Systemic FOLFIRI + target agent (bevacizumab or cetuximab) every 2 weeks, IV FOLFIRI+ target agent (bevacizumab or cetuximab) every 2 weeks
- Where
- South Korea
- Volunteers
- 100 people
- Sponsor
- Yonsei University
Colorectal Cancer, Liver Metastases
SBRT + PD-1 Monoclonal Antibody in Unresectable Colorectal Liver Metastases
To explore the efficacy and safety of stereotactic body radiation therapy (SBRT) combined with PD-1 monoclonal antibody in the treatment of unresectable colorectal cancer liver metastasis through a prospective study, providing…
- Trial name
- SPARKLE-L (NCT06794086)
- Testing
- Stereotactic body radiation therapy, PD-1 Monoclonal Antibody, Chemotherapy
- Where
- China
- Volunteers
- 24 people
- Sponsor
- Jun Huang
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.